Maternal Plasma Plasminogen Activator Inhibitor-2 at 11 to 13 Weeks of Gestation in Hypertensive Disorders of Pregnancy

REFERENCES

• Norris LA. Blood coagulation. Best Pract Res Clin Obstet Gynecol 2003; 17: 369–383.
   PubMed Web of Science ®Google Scholar
• Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16:153–168.
   PubMed Web of Science ®Google Scholar
• Astedt B, Hägerstrand I, Lecander I. Cellular localisation in placenta of placental type plasminogen activator inhibitor. Thromb Haemost 1986; 56:63–65.
   PubMed Web of Science ®Google Scholar
• Kruithof EK, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86:4007–4024.
   PubMed Web of Science ®Google Scholar
• Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69:460–466.
   PubMed Web of Science ®Google Scholar
• Coolman M, de Groot CJ, Steegers EA, Geurts-Moespot A, Thomas CM, Steegers-Theunissen RP, Sweep FC. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy. Eur J Obstet Gynecol Reprod Biol 2006; 128:22–8.
   PubMed Web of Science ®Google Scholar
• Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 1994; 101:488–492.
   PubMedGoogle Scholar
• WHO. Make every mother and child count. World Health Report, 2005. Geneva: World Health Organization, 2005.
   Google Scholar
• Lewis G, ed. Why mothers die 2000–2002: the sixth report of confidential enquiries into maternal deaths in the United Kingdom. London: RCOG Press, 2004.
   Google Scholar
• ACOG Committee on Practice Bulletins – Obstetrics. ACOG practice bulletin: diagnosis and management of preeclampsia and eclampsia: number 33, January 2002. Obstet Gynecol 2002; 99:159–167.
   PubMed Web of Science ®Google Scholar
• Brosens I, Robertson WB, Dixon HG. The physiological response of the vessels of the placental bed to normal pregnancy. J Pathol Bacteriol 1967; 93: 569–579.
   PubMedGoogle Scholar
• Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. BJOG 1986; 93:1049–1059.
   Web of Science ®Google Scholar
• Pijnenborg R, Anthony J, Davey DA, . Placental bed spiral arteries in the hypertensive disorders of pregnancy. BJOG 1991; 98:648–655.
   Web of Science ®Google Scholar
• Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 2005; 193:429–436.
   PubMed Web of Science ®Google Scholar
• Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11+0 to 13+6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2007; 30:742–749.
   PubMed Web of Science ®Google Scholar
• O'Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17:385–396.
   PubMed Web of Science ®Google Scholar
• Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74:1332–1338.
   PubMed Web of Science ®Google Scholar
• Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole. Br J Obstet Gynaecol 1993; 100:370–374.
   PubMedGoogle Scholar
• Koh SC, Anandakumar C, Montan S, Ratnam SS. Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia. Gynecol Obstet Invest 1993; 35:214–221.
   PubMed Web of Science ®Google Scholar
• Lindoff C, Astedt B. Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function. Am J Obstet Gynecol 1994; 171:60–64.
   PubMed Web of Science ®Google Scholar
• He S, Bremme K, Blombäck M. Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia. Blood Coagul Fibrinolysis 1995; 6:703–708.
   PubMed Web of Science ®Google Scholar
• Nakashima A, Kobayashi T, Terao T. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors. Gynecol Obstet Invest 1996; 42:95–101.
   PubMed Web of Science ®Google Scholar
• Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset PM, Wisløff F. Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia. Acta Obstet Gynecol Scand 1999; 78:191–197.
   PubMed Web of Science ®Google Scholar
• Roes EM, Sweep CG, Thomas CM, Zusterzeel PL, Geurts-Moespot A, Peters WH, Steegers EA. Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. Am J Obstet Gynecol 2002; 187:1019–1025.
   PubMed Web of Science ®Google Scholar
• Tanjung MT, Siddik HD, Hariman H, Koh SC. Coagulation and fibrinolysis in preeclampsia and neonates. Clin Appl Thromb Hemost 2005; 11:467–473.
   PubMed Web of Science ®Google Scholar
• Sartori MT, Serena A, Saggiorato G, Campei S, Faggian D, Pagnan A, Paternoster DM. Variations in fibrinolytic parameters and inhibin-A in pregnancy related hypertensive disorders. J Thromb Haemost 2008; 6:352–358.
   PubMed Web of Science ®Google Scholar
• Clausen T, Djurovic S, Reseland JE, Berg K, Drevon CA, Henriksen T. Altered plasma concentrations of leptin, transforming growth factor-beta(1) and plasminogen activator inhibitor type 2 at 18 weeks of gestation in women destined to develop pre-eclampsia. Circulating markers of disturbed placentation? Placenta 2002; 23:380–385.
   PubMed Web of Science ®Google Scholar
• Astedt B, Lindoff C, Lecander I. Significance of plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Semin Thromb Hemost. 1998; 24:431–435.
   PubMed Web of Science ®Google Scholar
• Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352:343–346.
   PubMed Web of Science ®Google Scholar
• Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin, and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 2008; 31:618–624.
   PubMed Web of Science ®Google Scholar
• Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20: IX–XIV.
   PubMed Web of Science ®Google Scholar